Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1973 2
1974 1
1978 1
1980 1
1981 4
1982 1
1983 4
1984 8
1985 11
1986 12
1987 5
1988 9
1989 8
1990 21
1991 11
1992 24
1993 19
1994 21
1995 45
1996 36
1997 46
1998 39
1999 57
2000 49
2001 74
2002 70
2003 74
2004 83
2005 98
2006 109
2007 121
2008 132
2009 122
2010 126
2011 140
2012 142
2013 179
2014 198
2015 209
2016 205
2017 207
2018 230
2019 236
2020 245
2021 272
2022 221
2023 212
2024 76

Text availability

Article attribute

Article type

Publication date

Search Results

3,740 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "MOGS-congenital disorder of glycosylation"
Page 1
Protein glycosylation in cancer.
Stowell SR, Ju T, Cummings RD. Stowell SR, et al. Annu Rev Pathol. 2015;10:473-510. doi: 10.1146/annurev-pathol-012414-040438. Annu Rev Pathol. 2015. PMID: 25621663 Free PMC article. Review.
Although genetic alterations underpin the development of neoplastic disease, epigenetic changes can exert an equally significant effect on neoplastic transformation. Among neoplasia-associated epigenetic alterations, changes in cellular glycosylation have recently r …
Although genetic alterations underpin the development of neoplastic disease, epigenetic changes can exert an equally significant effe …
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Luo G, et al. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409. doi: 10.1016/j.bbcan.2020.188409. Epub 2020 Aug 19. Biochim Biophys Acta Rev Cancer. 2021. PMID: 32827580 Review.
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker, predictor, and promoter in pancreatic cancer. ...As a promoter, CA19-9 could be used to evaluate the biology …
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. C …
MUC1: An emerging target in cancer treatment and diagnosis.
Qing L, Li Q, Dong Z. Qing L, et al. Bull Cancer. 2022 Nov;109(11):1202-1216. doi: 10.1016/j.bulcan.2022.08.001. Epub 2022 Sep 30. Bull Cancer. 2022. PMID: 36184332 Review.
MUC1 is a highly glycosylated transmembrane mucin on the luminal surface of epithelial cells, protecting them from extreme factors. ...MUC1 glycosylation insufficiency leads to exposure of novel antigenic epitopes that can be used as specific targets for therapy and …
MUC1 is a highly glycosylated transmembrane mucin on the luminal surface of epithelial cells, protecting them from extreme factors. . …
International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.
Altassan R, Péanne R, Jaeken J, Barone R, Bidet M, Borgel D, Brasil S, Cassiman D, Cechova A, Coman D, Corral J, Correia J, de la Morena-Barrio ME, de Lonlay P, Dos Reis V, Ferreira CR, Fiumara A, Francisco R, Freeze H, Funke S, Gardeitchik T, Gert M, Girad M, Giros M, Grünewald S, Hernández-Caselles T, Honzik T, Hutter M, Krasnewich D, Lam C, Lee J, Lefeber D, Marques-de-Silva D, Martinez AF, Moravej H, Õunap K, Pascoal C, Pascreau T, Patterson M, Quelhas D, Raymond K, Sarkhail P, Schiff M, Seroczyńska M, Serrano M, Seta N, Sykut-Cegielska J, Thiel C, Tort F, Vals MA, Videira P, Witters P, Zeevaert R, Morava E. Altassan R, et al. J Inherit Metab Dis. 2019 Jan;42(1):5-28. doi: 10.1002/jimd.12024. J Inherit Metab Dis. 2019. PMID: 30740725
Phosphomannomutase 2 (PMM2-CDG) is the most common congenital disorder of N-glycosylation and is caused by a deficient PMM2 activity. ...
Phosphomannomutase 2 (PMM2-CDG) is the most common congenital disorder of N-glycosylation and is caused by a deficient PMM2 ac …
Congenital disorders of glycosylation: narration of a story through its patents.
Monticelli M, D'Onofrio T, Jaeken J, Morava E, Andreotti G, Cubellis MV. Monticelli M, et al. Orphanet J Rare Dis. 2023 Aug 29;18(1):247. doi: 10.1186/s13023-023-02852-w. Orphanet J Rare Dis. 2023. PMID: 37644541 Free PMC article. Review.
Congenital disorders of glycosylation are a group of more than 160 rare genetic defects in protein and lipid glycosylation. ...
Congenital disorders of glycosylation are a group of more than 160 rare genetic defects in protein and lipid glycosylation …
Congenital disorders of glycosylation and infantile epilepsy.
Lee HF, Chi CS. Lee HF, et al. Epilepsy Behav. 2023 May;142:109214. doi: 10.1016/j.yebeh.2023.109214. Epub 2023 Apr 21. Epilepsy Behav. 2023. PMID: 37086590 Review.
Congenital disorders of glycosylation (CDG) are a group of rare inherited metabolic disorders caused by defects in various defects of protein or lipid glycosylation pathways. ...
Congenital disorders of glycosylation (CDG) are a group of rare inherited metabolic disorders caused by defects in vari …
Perspectives on Glycosylation and Its Congenital Disorders.
Ng BG, Freeze HH. Ng BG, et al. Trends Genet. 2018 Jun;34(6):466-476. doi: 10.1016/j.tig.2018.03.002. Epub 2018 Mar 29. Trends Genet. 2018. PMID: 29606283 Free PMC article. Review.
Congenital disorders of glycosylation (CDG) are a rapidly expanding group of metabolic disorders that result from abnormal protein or lipid glycosylation. ...We highlight recent advancements that have resulted in a better understanding of human glyc …
Congenital disorders of glycosylation (CDG) are a rapidly expanding group of metabolic disorders that result from abnor …
What is new in CDG?
Jaeken J, Péanne R. Jaeken J, et al. J Inherit Metab Dis. 2017 Jul;40(4):569-586. doi: 10.1007/s10545-017-0050-6. Epub 2017 May 8. J Inherit Metab Dis. 2017. PMID: 28484880 Review.
Congenital disorders of glycosylation (CDG) are one group among the disorders of glycosylation. ...Genetic diseases with hypoglycosylation can be divided in primary congenital disorders of glycosylation (CDG) and in genetic diseases causi …
Congenital disorders of glycosylation (CDG) are one group among the disorders of glycosylation. ...Genetic disea …
Altered Glycosylation in Progression and Management of Bladder Cancer.
Wilczak M, Surman M, Przybyło M. Wilczak M, et al. Molecules. 2023 Apr 13;28(8):3436. doi: 10.3390/molecules28083436. Molecules. 2023. PMID: 37110670 Free PMC article. Review.
Therefore, there is a need to deepen our understanding of the molecular mechanisms underlying BC progression to develop new diagnostic and therapeutic tools. One such mechanism is protein glycosylation. Numerous studies reported changes in glycan biosynthesis during neopla …
Therefore, there is a need to deepen our understanding of the molecular mechanisms underlying BC progression to develop new diagnostic and t …
Altered glycosylation in pancreatic cancer and beyond.
Lumibao JC, Tremblay JR, Hsu J, Engle DD. Lumibao JC, et al. J Exp Med. 2022 Jun 6;219(6):e20211505. doi: 10.1084/jem.20211505. Epub 2022 May 6. J Exp Med. 2022. PMID: 35522218 Free PMC article. Review.
Aberrant glycosylation is a feature of cancer progression and influences a broad range of signaling pathways to promote disease onset and progression. ...A deeper understanding of the functional consequences of altered glycosylation will facilitate future hyp …
Aberrant glycosylation is a feature of cancer progression and influences a broad range of signaling pathways to promote disease …
3,740 results